<DOC>
	<DOCNO>NCT02381990</DOCNO>
	<brief_summary>Registration Prostate Cancer patient undergo Prostate Cryotherapy guide Mutiparametric-MRI ( MP-MRI ) highlight biopsy confirm region . The primary outcome measure 5 year oncological control . Secondary aim lack progression beyond prostate gland . The aim intervention eradicate prostate cancer disease treat area impose minimal deleterious effect quality life .</brief_summary>
	<brief_title>Fuse Image MRI Guided Prostate Cryotherapy</brief_title>
	<detailed_description>CLINICAL TRIAL OF OBSERVATION NATURE PRIMARY OUTCOME Cancer control treat area 5 year intervention base prostate biopsy initial treat area SECONDARY OUTCOMES Lack cancer presence progression 5 year initial intervention MP-MRI imaging ; urinary sexual function change quality life ; anxiety related cancer cancer control , number biopsy require study period ; need treatment prostate cancer ; treatment tolerance local anesthesia DATA COLLECTION - Complete H &amp; P , family history , past medical surgical history , social history , allergy , medication - Procedure Specifics Assessing Prostate , Seminal Vesicles Urethral Contouring MP-MRI . Dominant lesion secondary lesion contour MP-MRI . Co-Registration quality , date procedure , cryoprobes use , freeze/thaw cycle time , temperature neurovascular bundle , denonvilliers fascia . Urethral warmer requirement - Follow information : 30 day perioperative outcome ( incidence UTI , urinary retention , failure local anesthetic , pain measure ) . 6 week , 3,6,9,12 month every 6 month measure PSA , Testosterone level , Urinary Function Sexual Function inventory , Overall anxiety regret related diagnosis treatment - Uroflow PVR measurement 3 6 month treatment - MP MRI yearly basis , year 2,3,4 treatment , biopsy driven new suspicious MRI finding - MP MRI trigger elevation PSA velocity PSA level 10 % diagnosis - Transperineal Fusion Guided Prostate biopsy 1st year - emphasis treat area , suspicious MRI area - Transperineal Fusion Guided Prostate biopsy 5th year - emphasis treat area , suspicious MRI area SAFETY MEASURES - Periodic evaluation registry ensure consistency follow - Patient remainder test require</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Men 55 65 year age clinical diagnosis prostate cancer Low Intermediate risk prostate cancer , &lt; 50 % positive core rate prostate lobe Men older 65 year age clinical diagnosis prostate cancer &lt; 50 % positive core rate prostate lobe Absence extracapsular extension Absence seminal vesicle invasion Absence regional distant metastatic disease Multiparametric MRI prostate perform either biopsy &gt; 10 week prostate biopsy Treated Cryotherapy prostate Treatment base coregistration MPMRI Prostate Ultrasound Prior treatment prostate cancer form surgery . Performance status great 0 base ECOG criterion Mental status impairment</criteria>
	<gender>Male</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Prostate</keyword>
	<keyword>PSA</keyword>
	<keyword>FUSION</keyword>
	<keyword>Ultrasound</keyword>
	<keyword>MRI</keyword>
	<keyword>Cancer</keyword>
	<keyword>Cryotherapy</keyword>
	<keyword>Outcomes</keyword>
	<keyword>Recurrence</keyword>
	<keyword>QOL , Quality Life</keyword>
	<keyword>Urinary function</keyword>
	<keyword>Sexual Function</keyword>
</DOC>